TransCode Therapeutics Price Chart
TransCode Therapeutics Volume Chart
TransCode Therapeutics Market Segments
After Hours
*No Trades in Segment
Regular Trading Hours
-0.34(-4.05%)
| Open | $8.40 |
|---|---|
| Close | $8.06 |
| Low | $7.97 |
| Low Change | -0.43 (-5.12%) |
| High | $8.40 |
| High Change | +0.00 (+0.00%) |
| Range | $0.43 |
| Volume | 4.024K |
| Dollar Volume | $32.43K |
Premarket
*No Trades in Segment
After Hours Yesterday
*No Trades in Segment
Regular Trading Hours Yesterday
-0.20(-2.32%)
| Open | $8.40 |
|---|---|
| Close | $8.21 |
| Low | $8.20 |
| Low Change | -0.20 (-2.38%) |
| High | $9.30 |
| High Change | +0.90 (+10.71%) |
| Range | $1.10 |
| Volume | 9.609K |
| Dollar Volume | $78.84K |
Premarket Yesterday
*No Trades in Segment
TransCode Therapeutics Moving Averages
| 5 Day Moving Average (SMA5) | $8.45 |
|---|---|
| 10 Day Moving Average (SMA10) | $8.64 |
| 20 Day Moving Average (SMA20) | $8.69 |
| 50 Day Moving Average (SMA50) | $9.16 |
| 100 Day Moving Average (SMA100) | $8.99 |
| 200 Day Moving Average (SMA200) | $9.92 |
TransCode Therapeutics Statistics
| Average Volume (30 Days) | 6.49K |
|---|---|
| P/E Ratio (Current) | -.21 |
| EPS (Current) | -$39.56 |
| Dividend Yield | 0.00% |
| Free Cash Flow | -$19.52M |
| Cash Ratio | 5.10 |
| Current Ratio | 6.29 |
| Quick Ratio | 6.29 |
| Debt to Equity | 0.00 |
| Enterprise Value | -$10.07M |
| EV to EBITDA | 0.53 |
| EV to Sales | — |
| Price to Book | 0.75 |
| Price to Cash Flow | — |
| Price to Free Cash Flow | — |
| Price to Sales | — |
| Return on Assets | -0.22% |
| Return on Equity | -3.51% |
TransCode Therapeutics Stock Splits
There have been 4 stock splits for TransCode Therapeutics (RNAZ). The last reverse stock split occured on May 15, 2025 and reduced the outstanding shares at a ratio of 28:1.
| Date | Type | Ratio |
|---|---|---|
| May 15, 2025 | Reverse | 28:1 |
| Dec 4, 2024 | Reverse | 33:1 |
| Jan 16, 2024 | Reverse | 40:1 |
| May 23, 2023 | Reverse | 20:1 |
TransCode Therapeutics Dividends
There have been no dividends for TransCode Therapeutics (RNAZ).